Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis

Cho, 2015, Microplate alamar blue assay (MABA) and low oxygen recovery assay (LORA) for Mycobacterium tuberculosis, Methods Mol. Biol., 1285, 281, 10.1007/978-1-4939-2450-9_17 Cilfone, 2013, Multi-scale modeling predicts a balance of tumor necrosis factor-alpha and interleukin-10 controls the granuloma environment during Mycobacterium tuberculosis infection, PLoS One, 8, e68680, 10.1371/journal.pone.0068680 Cohen, 2010, Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment, Br. J. Clin. Pharmacol., 69, 143, 10.1111/j.1365-2125.2009.03570.x Dowty, 2014, Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis, J. Pharmacol. Exp. Ther., 348, 165, 10.1124/jpet.113.209304 Driver, 2012, Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis, Antimicrob. Agents Chemother., 56, 3181, 10.1128/AAC.00217-12 Ghoreschi, 2011, Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550), J. Immunol., 186, 4234, 10.4049/jimmunol.1003668 Gupta, 2013, Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor, Am. J. Respir. Crit. Care Med., 188, 600, 10.1164/rccm.201304-0650OC Irwin, 2014, Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas, Antimicrob. Agents Chemother., 58, 4026, 10.1128/AAC.02565-14 Kubo, 2014, The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells, Ann. Rheum. Dis., 73, 2192, 10.1136/annrheumdis-2013-203756 Lee, 2014, Tofacitinib versus methotrexate in rheumatoid arthritis, N. Engl. J. Med., 370, 2377, 10.1056/NEJMoa1310476 Lin, 2010, Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model, Arthritis Rheum., 62, 340 Maiga, 2012, Risk of tuberculosis reactivation with tofacitinib (CP-690550), J. Infect. Dis., 205, 1705, 10.1093/infdis/jis269 Manca, 2013, Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection, PLoS One, 8, e74082, 10.1371/journal.pone.0074082 Marino, 2015, Macrophage polarization drives granuloma outcome during Mycobacterium tuberculosis infection, Infect. Immun., 83, 324, 10.1128/IAI.02494-14 Marzo, 2014, Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis, Tuberculosis (Edinb.), 94, 55, 10.1016/j.tube.2013.09.004 Matheny, 2004, Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues, Drug Metab. Dispos., 32, 1008 McCune, 1956, Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy, J. Exp. Med., 104, 737, 10.1084/jem.104.5.737 McCune, 1957, Ineffectiveness of isoniazid in modifying the phenomenon of microbial persistence, Am. Rev. Tuberc., 76, 1106 Pan, 2005, Ipr1 gene mediates innate immunity to tuberculosis, Nature, 434, 767, 10.1038/nature03419 Pattison, 2012, Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback, J. Immunol., 189, 2784, 10.4049/jimmunol.1200310 Pesu, 2008, Therapeutic targeting of Janus kinases, Immunol. Rev., 223, 132, 10.1111/j.1600-065X.2008.00644.x Pichugin, 2009, Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts, Am. J. Pathol., 174, 2190, 10.2353/ajpath.2009.081075 Robertson, 2012, Detection and treatment of subclinical tuberculosis, Tuberculosis (Edinb.), 92, 447, 10.1016/j.tube.2012.06.004 Rosenthal, 2012, Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis, Antimicrob. Agents Chemother., 56, 4331, 10.1128/AAC.00912-12 Salgado, 2011, The risk of tuberculosis in patients treated with TNF antagonists, Expert. Rev. Clin. Immunol., 7, 329, 10.1586/eci.11.6 Sandborn, 2012, Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis, N. Engl. J. Med., 367, 616, 10.1056/NEJMoa1112168 Sewgobind, 2010, The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells, Am. J. Transplant., 10, 1785, 10.1111/j.1600-6143.2010.03200.x Skerry, 2012, Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas, PLoS One, 7, e39680, 10.1371/journal.pone.0039680 Skinner, 1994, A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions, Antimicrob. Agents Chemother., 38, 2557, 10.1128/AAC.38.11.2557 Traynor, 2012, FDA approves tofacitinib for rheumatoid arthritis, Am. J. Health Syst. Pharm., 69, 2120 Vilaplana, 2013, Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis, J. Infect. Dis., 208, 199, 10.1093/infdis/jit152 Wallis, 2004, A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis, AIDS, 18, 257, 10.1097/00002030-200401230-00015 Yan, 2007, Progression of pulmonary tuberculosis and efficiency of bacillus Calmette–Guerin vaccination are genetically controlled via a common sst1-mediated mechanism of innate immunity, J. Immunol., 179, 6919, 10.4049/jimmunol.179.10.6919